Riskpilot← Back to searchSign inGet full accessIXI science AB
ABActiveOrg 5594411745Economic activity was not specified by tax authority · NACE 0000Est. 20230 employees
Revenue 2024
SEK 0
EBITDA margin
—
Equity ratio
100.0%
Financial strength
Net profit 2024
—
0 employees
| Revenue | SEK 0 | — |
| EBITDA | — | — |
| Net profit | — | — |
| Total assets | SEK 25K | — |
| Equity | SEK 25K | — |
| Employees | 0 | — |
Legal name
IXI science AB
Org number
5594411745
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
6 juli 2023
Share capital
SEK 25 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget avser ägna sig åt internationell samverkan, utveckling, forskning, promotion och handel med farmakologiska produkter och därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2024 |
|---|---|
| Revenue | 0 |
| Staff expenses | — |
| EBITDA | — |
| Depreciation & amort. | — |
| EBIT | 0 |
| Net financials | — |
| Profit before tax | 0 |
| Tax | — |
| Net profit | — |
| Item | 2024 |
|---|---|
| Total assets | 25 |
| Equity | 25 |
| Long-term debt | — |
| Short-term debt | — |
| Total debt | — |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20242024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20242024
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20242024
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20242024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20242024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20242024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-06 – 2024-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
NL Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
JD Audit | Audit | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2024 | — | — | |
| Board of Directors | 2023 | — | — | |
| Deputy Board Member | 2024 | — | — | |
| Deputy Board Member | 2024 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Deputy Board Member | 2023 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of IXI science AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Nils Lennart Lelle Hagström | Chief Executive Officer | 0 companies |
| Jan Daniel Hellström | Audit | 0 companies |
| Fahimeh Amiri | Chairman | 0 companies |
| M H Charlotte Wiberg Larsson | Board of Directors | 0 companies |
| Nick Hagström | Deputy Board Member | 0 companies |
| Davoud Amiri | Deputy Board Member | 0 companies |
| Peter Jonas Michael Carlborg | Deputy Board Member | 0 companies |
| Bo Torsten Patrik Nilsson | Deputy Board Member | 0 companies |